{"id":"olanzapine-nk-1-ra-5-ht3-ra","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Metabolic effects (hyperglycemia, dyslipidemia)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. NK-1 receptor antagonists block substance P signaling, which plays a role in nausea and emesis. 5-HT3 receptor antagonists (ondansetron-class) directly block chemoreceptor trigger zone signaling. The combination targets multiple pathways involved in chemotherapy-induced nausea and vomiting (CINV) and may address concurrent psychiatric symptoms.","oneSentence":"This combination blocks dopamine/serotonin (olanzapine), substance P signaling (NK-1 RA), and serotonin 5-HT3 receptors to reduce nausea, vomiting, and potentially improve psychiatric symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:24:03.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) in cancer patients"},{"name":"Nausea and vomiting in patients with concurrent psychiatric conditions"}]},"trialDetails":[{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Olanzapine+NK-1 RA+5-HT3 RA","genericName":"Olanzapine+NK-1 RA+5-HT3 RA","companyName":"Fifth Affiliated Hospital, Sun Yat-Sen University","companyId":"fifth-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks dopamine/serotonin (olanzapine), substance P signaling (NK-1 RA), and serotonin 5-HT3 receptors to reduce nausea, vomiting, and potentially improve psychiatric symptoms. Used for Chemotherapy-induced nausea and vomiting (CINV) in cancer patients, Nausea and vomiting in patients with concurrent psychiatric conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}